Loading company…
Yizun Biomedical develops cell therapies for cancer and other immune-related conditions.
Established in 2018 and based in Hangzhou, China, Yizun Biomedical develops cell therapies using its CNK-T, VAC-T and U-T technology platforms. The therapies are being developed for solid and blood cancers, autoimmune diseases and viral infections. In April 2024, the company raised approximately CNY 100 million in Series A+ funding. It planned to use the funds for clinical research, regulatory submissions and team expansion in China and the US.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in